Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark. / Rasmussen, Line Dahlerup; Lebech, Anne Mette; Øvrehus, Anne; Poulsen, Birgitte Klindt; Christensen, Hanne Rolighed; Nielsen, Henrik; Johansen, Isik Somuncu; Omland, Lars Haukali; Wiese, Lothar; Helleberg, Marie; Storgaard, Merete; Dalager-Pedersen, Michael; Rasmussen, Thomas A.; Benfield, Thomas; Petersen, Tonny Studsgaard; Andersen, Åse Bengård; Gram, Mie Agermose; Stegger, Marc; Edslev, Sofie Marie; Obel, Niels.
In: British Journal of Clinical Pharmacology, Vol. 89, No. 6, 2023, p. 1820-1833.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark
AU - Rasmussen, Line Dahlerup
AU - Lebech, Anne Mette
AU - Øvrehus, Anne
AU - Poulsen, Birgitte Klindt
AU - Christensen, Hanne Rolighed
AU - Nielsen, Henrik
AU - Johansen, Isik Somuncu
AU - Omland, Lars Haukali
AU - Wiese, Lothar
AU - Helleberg, Marie
AU - Storgaard, Merete
AU - Dalager-Pedersen, Michael
AU - Rasmussen, Thomas A.
AU - Benfield, Thomas
AU - Petersen, Tonny Studsgaard
AU - Andersen, Åse Bengård
AU - Gram, Mie Agermose
AU - Stegger, Marc
AU - Edslev, Sofie Marie
AU - Obel, Niels
N1 - Publisher Copyright: © 2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
PY - 2023
Y1 - 2023
N2 - Aims: To evaluate the experience with use of sotrovimab following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in high-risk groups. Methods: In a nationwide, population-based cohort study, we identified all individuals treated with sotrovimab (N = 2933) and stratified them by 4 high-risk groups: (A) malignant haematological disease, (B) solid organ transplantation, (C) anti-CD20 therapy ≤1 year and (D) other risks. Cox regression analysis was used to calculate hazard ratios for hospitalization, death and associated prognostic factors. Results: Of 2933 sotrovimab-treated individuals, 83% belonged to high-risk groups (37.6% haematological malignancy, 27.4% solid organ transplantation and 17.5% treatment with anti-CD20 ≤1 year). Only 17.8% had other risks (11.8% were pregnant, 10.7% primary immunodeficiency, 21.2% other malignancy, 4.3% received anti-CD20 >1 year and 52.0% other/unknown causes). Within 90 days of infusion, 30.2% were hospitalized and 5.3% died. The main prognostic factors were the predefined high-risk groups, mainly malignant haematological disease and age ≥65 years. Number of COVID-19 vaccines (≥3) was associated with a decreased risk of hospitalization. The Delta but not the Omicron BA.2 variant was associated with a higher risk of death compared to the BA.1 variant. Conclusion: More than 90% of the patients treated with sotrovimab belonged to the very high-risk groups as described in the Danish guidelines. Sotrovimab-treated individuals remained at a high risk of hospitalization and death which was strongly associated with the underlying immunocompromised state and age. Having received >3 COVID-19 vaccines was association with decreased risk of death and hospitalization.
AB - Aims: To evaluate the experience with use of sotrovimab following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in high-risk groups. Methods: In a nationwide, population-based cohort study, we identified all individuals treated with sotrovimab (N = 2933) and stratified them by 4 high-risk groups: (A) malignant haematological disease, (B) solid organ transplantation, (C) anti-CD20 therapy ≤1 year and (D) other risks. Cox regression analysis was used to calculate hazard ratios for hospitalization, death and associated prognostic factors. Results: Of 2933 sotrovimab-treated individuals, 83% belonged to high-risk groups (37.6% haematological malignancy, 27.4% solid organ transplantation and 17.5% treatment with anti-CD20 ≤1 year). Only 17.8% had other risks (11.8% were pregnant, 10.7% primary immunodeficiency, 21.2% other malignancy, 4.3% received anti-CD20 >1 year and 52.0% other/unknown causes). Within 90 days of infusion, 30.2% were hospitalized and 5.3% died. The main prognostic factors were the predefined high-risk groups, mainly malignant haematological disease and age ≥65 years. Number of COVID-19 vaccines (≥3) was associated with a decreased risk of hospitalization. The Delta but not the Omicron BA.2 variant was associated with a higher risk of death compared to the BA.1 variant. Conclusion: More than 90% of the patients treated with sotrovimab belonged to the very high-risk groups as described in the Danish guidelines. Sotrovimab-treated individuals remained at a high risk of hospitalization and death which was strongly associated with the underlying immunocompromised state and age. Having received >3 COVID-19 vaccines was association with decreased risk of death and hospitalization.
KW - COVID-19
KW - mAB
KW - SARS-CoV-2
KW - SARS-CoV-2 vaccines
KW - sotrovimab
U2 - 10.1111/bcp.15644
DO - 10.1111/bcp.15644
M3 - Journal article
C2 - 36519217
AN - SCOPUS:85146334563
VL - 89
SP - 1820
EP - 1833
JO - British Journal of Clinical Pharmacology, Supplement
JF - British Journal of Clinical Pharmacology, Supplement
SN - 0264-3774
IS - 6
ER -
ID: 341060524